In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells(448 views) Pisano M, De Paola I, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C
Anticancer Res (ISSN: 0250-7005, 0250-0700, 1791-7530electronic), 2013 Mar; 33(3): 871-879.
Keywords: Cell Adhesion, Cell Migration, Integrin V 3, Malignant Melanoma, Rgd Peptide, Antineoplastic Agent, Rgdechi Hcit, Unclassified Drug, Vitronectin Receptor, Antineoplastic Activity, Article, Cell Proliferation, Cytofluorometry, Human, Human Cell, In Vitro Study, Melanoma Cell, Priority Journal, Protein Expression, Angiogenesis Inhibitors, Cell Line, Tumor, Cell Movement, Integrin Alphavbeta3, Integrin Av 3, Pharmacology, Drug Effects, Analysis, Antagonists, Drug Therapy, Pathology, Secondary,
Affiliations: *** IBB - CNR ***
Institute of Biomolecular Chemistry-National Research Council of Italy, Traversa La Crucca 3, 07100 Sassari, Italy
Institute of Biostructures and Bioimaging-National Research Council of Italy, Napoli, Italy
Sardinia Research Laboratories Porto Conte Ricerche, Alghero, Italy
Service of Epidemiology, Local Health Unit 1, Sassari, Italy
Institute of Pathology, University Health Unit, Sassari, Italy
Institute of Crystallography-National Research Council of Italy, Bari, Italy
Istituto di Chimica Biomolecolare-CNR, Traversa La Crucca 3, 07100 Sassari, Italy. marina.pisano@icb.cnr.it,
References: MacKie, R. M., Hauschild, A., Eggermont, A. M., Epidemiology of invasive cutaneous melanoma (2009) Ann Oncol, 20 (SUPPL. 6), pp. vi1-vi
Berwick, M., Erdei, E., Hay, J., Melanoma epidemiology and public health (2009) Dermatol Clin, 27, pp. 205-214
Bhatia, S., Tykodi, S. S., Thompson, J. A., Treatment of metastatic melanoma: An overview (2009) Oncology, 23, pp. 488-496
Desgrosellier, J. S., Cheresh, D. A., Integrins in cancer: Biological implications and therapeutic opportunities (2010) Nature Rev Cancer, 10, pp. 9-22
Avraamides, C. J., Garmy-Susini, B., Varner, J., Integrins in angiogenesis and lymphangiogenesis (2008) Nature Rev Cancer, 8, pp. 604-617
Marshall, J. F., Rutherford, D. C., Happerfield, L., Hanby, A., McCartney, A. C., Newton-Bishop, J., Hart, I. R., Comparative analysis of integrins in vitro and in vivo in uveal and cutaneous melanomas (1998) Br J Cancer, 77, pp. 522-529
McGary, C., Chelouche Lev, D., Bar-Eli, M., Cellular adhesion pathways and metastatic potential of human melanoma (2002) Cancer Biol Ther, 1 (5), pp. 459-465
Kuphal, S., Bauer, R., Bosserhoff, A. K., Integrin signaling in malignant melanoma (2005) Cancer Metastasis Rev, 2, pp. 195-222
Jin, H., Varner, J., Integrins: Roles in cancer development and as treatment targets (2004) Br J Cancer, 90, pp. 561-565
Hood, J. D., Cheresh, D. A., Role of integrins in cell invasion and migration (2002) Nat Rev Cancer, 2, pp. 91-100
Mizejewski, G. J., Role of integrins in cancer: Survey of expression patterns (1999) Proc Soc Exp Biol Med, 222, pp. 124-138
Xiong, J. P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S. L., Arnaout, M. A., Crystal structure of the extracellular segment of integrin v 3 in complex with an Arg-Gly-Asp ligand (2002) Science, 296, pp. 151-155
Marinelli, L., Gottschalk, K. E., Meyer, A., Novellino, E., Kessler, H., Human integrin v 5 homology modeling and ligand binding (2004) J Med Chem, 47, pp. 4166-4177
Cox, D., Brennan, M., Moran, N., Integrins as therapeutic targets: Lessons and opportunities (2010) Nat Rev Drug Discov, 9 (10), pp. 804-820
Tamkun, J. W., Desimone, D. W., Fonda, D., Patel, R. S., Buck, C., Horwitz, A. F., Hynes, R. O., Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin (1986) Cell, 46, pp. 271-282
Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H., N-Methylated cyclic RGD peptides as highly active and selective v 3 integrin antagonists (1999) J Med Chem, 42 (16), pp. 3033-3040
Reardon, D. A., Neyns, B., Weller, M., Tonn, J. C., Nabors, L. B., Stupp, R., Cilengitide: An RGD pentapeptide v 3 and v 5 integrin inhibitor in development for glioblastoma and other malignancies (2011) Future Oncol, 7 (3), pp. 339-354
Tabatabai, G., Weller, M., Nabors, B., Picard, M., Reardon, D., Mikkelsen, T., Ruegg, C., Stupp, R., Targeting integrins in malignant glioma (2010) Target Oncol, 5, pp. 175-181
Perdih, A., Dolenc, M. S., Small molecule antagonists of integrin receptors (2010) Curr Med Chem, 17 (22), pp. 2371-2392
Del Gatto, A., Zaccaro, L., Grieco, P., Novellino, E., Zannetti, A., Del Vecchio, S., Iommelli, F., Saviano, M., Novel and selective v 3 receptor peptide antagonist: Design, synthesis, and biological behavior (2006) J Med Chem, 49, pp. 3416-3420
Santulli, G., Basilicata, M. F., De Simone, M., Del Giudice, C., Anastasio, A., Sorriento, D., Saviano, M., Iaccarino, G., Evaluation of the antiangiogenic properties of the new selective v 3 integrin antagonist RGDechi-hCit (2011) J Transl Med, 9, p. 7
Lu, H., Murtagh, J., Schwartz, E. L., The microtubule binding drug laulimalide inhibits vascular endothelial growth factorinduced human endothelial cell migration and is synergistic when combined with docetaxel (Taxotere) (2006) Mol Pharmacol, 69, pp. 1207-1215
Astrof, S., Hynes, R. O., Fibronectins in vascular morphogenesis (2009) Angiogenesis, 12, pp. 165-175
Oliveira-Ferrer, L., Hauschild, J., Fiedler, W., Bokemeyer, C., Nippgen, J., Celik, I., Schuch, G., Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway (2008) J Exp Clin Cancer Res, 27, p. 86
Sadatmousavi, P., Soltani, M., Nazarian, R., Jafari, M., Chen, P., Self-assembling peptides: Potential role in tumor targeting (2011) Curr Pharm Biotechnol, 12 (8), pp. 1089-1100
Zaccaro, L., Del Gatto, A., Pedone, C., Saviano, M., Peptides for tumour therapy and diagnosis: Current status and future directions (2009) Curr Med Chem, 16, pp. 780-795
Palmieri, G., Casula, M., Sini, M. C., Ascierto, P. A., Cossu, A., Issues affecting molecular staging in the management of patients with melanoma (2007) J Cell Mol Med, 11, pp. 1052-1068
Kueng, W., Silber, E., Eppenberger, U., Quantification of cells cultured on 96-well plates (1989) Anal Biochem, 182, pp. 16-19
Pisano, M., Pagnan, G., Loi, M., Mura, M. E., Tilocca, M. G., Palmieri, G., Fabbri, D., Rozzo, C., Antiproliferative and pro-apoptotic activity of eugenol-related biphenyls on malignant melanoma cells (2007) Mol Cancer, 6, p. 8
In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells
Background: In malignant melanoma (MM), overexpression of alpha (v) beta (3) integrin is linked to a more metastatic phenotype. Development of anti-alpha (v) beta (3) agents able to counteract melanoma progression would be helpful for disease treatment. A new selective ligand of alpha (v) beta (3), RGDechi-hCit, has anti-angiogenic properties against endothelial cells in animal angiogenesis models. The aim of this study was to evaluate the in vitro effects of the RGDechi-hCit peptide on MM cell lines. Materials and Methods: Cytofluorimetric analysis characterized the cell surface expression of alpha (v) beta (3) integrin on seven MM cell lines: A375, WM266-4, SK-Mel-28, Sbcl2, LB24Dagi, PR-Mel and PNP-Mel. Cell proliferation, adhesion, and migration assays were carried out using the alpha (v) beta (3) -antagonist RGDechi-hCit. Results: Proliferation was not significantly inhibited by RGDechi-hCit, although striking morphological changes were detected in MM cell lines highly expressing alpha (v) beta (3). Conversely, assays on fibronectin-coated plates showed a significant RGDechi-hCit dose-dependent inhibitory effect on both adhesion and migration. Conclusion: The data demonstrate anti-adhesion and anti-migration, but not antiproliferative, activities of RGDechi-hCit against MM cells
In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(288 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote